Paul Maffuid
Vice President Pharmaceutical Development at MabVax Therapeutics; Inc. - , California, United States
Paul Maffuid's Colleagues at MabVax Therapeutics; Inc.
Paul Maffuid's Contact Details
["8582599405","8332086789","8585008468818575","18582599405","7815952920","5707088780","9089381475"]
MabVax Therapeutics; Inc.
Paul Maffuid's Company Details
MabVax Therapeutics (Nasdaq: MBVX) is a clinical-stage biotechnology company with a fully human antibody discovery platform focused on the rapid translation into clinical development of products to address unmet medical needs in the treatment of cancer. Our antibody MVT-5873, is a fully human IgG1 monoclonal antibody (mAb) that targets sialyl Lewis A (sLea), an epitope on CA19-9, and is currently in Phase 1 clinical trials as a therapeutic agent for patients with pancreatic cancer and other CA19-9 positive tumors. With our collaborators including Memorial Sloan Kettering Cancer Center, Rockefeller University, Sarah Cannon Research Institute, Honor Health and Imaging Endpoints, we have treated 50 patients with either our therapeutic antibody designated as MVT-5873 or our PET imaging diagnostic product designated as MVT-2163 in Phase 1 clinical studies, and demonstrated early safety, specificity for the target and a potential efficacy signal. Patient dosing has commenced for our lead development program in Phase 1 clinical study of the Company's radioimmunotherapy product MVT-1075.